Skip to content

Coffee After Pancreatic Surgery

Coffee After Pancreatic Surgery - a Randomised, Single Blinded, Placebo-controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04205058
Acronym
COPS
Enrollment
204
Registered
2019-12-19
Start date
2020-01-05
Completion date
2025-01-05
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bowel Dysfunction, Pancreatic Diseases, Postoperative Complications, Postoperative Ileus

Keywords

Randomised clinical trial, Pancreatic surgery

Brief summary

Postoperative ileus is a common complication after major abdominal surgery. A positive effect of coffee to bowel movement has been described after colorectal and gynecologic interventions. The objective of this randomised controlled trial is to investigate whether the implementation of a fast track protocol with early coffee consumption accelerates the recovery of bowel function after pancreaticoduodenectomy.

Detailed description

Postoperative ileus (POI) is a common disorder after major abdominal surgery, affecting up to 40% of patients undergoing laparotomy. POI is described as the time between surgery and the first passage of flatus and/or stool and tolerance of oral diet. It could be recognised as postoperative complication when is defined as two or more of nausea/vomiting, inability to tolerate oral diet over 24 h, absence of flatus over 24 h, abdominal distention and radiologic confirmation on or after day 4 postoperatively without prior resolution. Multimodal approaches have been described to treat POI; among them, the early consumption of coffee showed a substantial benefit after colorectal and gynecologic surgery. The objective of this randomised trial is to investigate whether early coffee consumption can accelerate the recovery of bowel function after open pancreaticoduodenectomy.

Interventions

DIETARY_SUPPLEMENTStandard coffee

One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).

DIETARY_SUPPLEMENTCaffeine-free coffee

One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).

DIETARY_SUPPLEMENTDrinking water

One 30 mL espresso cup administered twice a day (08.00 a.m. and 02.00 p.m.).

Sponsors

Azienda Ospedaliera Universitaria Integrata Verona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Masking description

Participants and staff were masked about the type of coffee administrated (standard coffee versus caffeine-free coffee). Masking about administration of hot water is not feasible.

Intervention model description

randomised, partilly blinded trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Elective open pancreaticoduodenectomy * Age ≥ 18 years * American Society Anesthesiologists (ASA) score ≤ 3 * Ability of the subject to understand aims and clinical consequences of the trial * Written informed consent

Exclusion criteria

* American Society Anesthesiologists (ASA) score ≥ 4 * Need for early postoperative Intensive Care Unit care * Need for naso-gastric tube on postoperative day one * Intolerance to coffee * Refuse to assume coffee * Pregnancy * Surgical procedures performed different from pancreaticoduodenectomy * Impaired mental status or language problems

Design outcomes

Primary

MeasureTime frameDescription
First Bowel Movement96 hours.Time to first bowel movement (expressed by hours from the time of surgical procedure ending).

Secondary

MeasureTime frameDescription
First Flatus96 hoursTime to first flatus (expressed by hours from the time of surgical procedure ending).
Tolerance to solid food96 hoursTime to tolerance to solid food (expressed by hours from the time of surgical procedure ending). Tolerance was defined as the ability to eat at least half of the solid food served by hospital staff.
Length of stay90 daysLength of stay expressed by days from intervention to discharge.

Countries

Italy

Contacts

PRINCIPAL_INVESTIGATORGiuseppe Malleo, MD PhD

Azienda Ospedaliera Universitaria Integrata Verona

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 9, 2026